Leader ship
Co-founder and Chairman
Hongtao Yu, Ph.D. co-founded Westlake Pharmaceuticals in 2020 and serves as its Chairman.
Dr. Yu is a world-renowned cell biologist. Now he serves as the Dean of Westlake University’s School of Life Sciences and the Director of Westlake Laboratory of Life Sciences and Biomedicine (WLLSB).
He is a recipient of the Chang Jiang Scholars Program Chair Professorship，and was selected for the Zhejiang Province Kunpeng Plan, and the New Cornerstone Investigator Program.
Dr. Yu received his bachelor’s degree in chemistry from Peking University and received his Ph.D. in chemistry from Harvard University. Dr. Yu began his independent research career in Department of Pharmacology at University of Texas Southwestern Medical Center, and was promoted to Associate Professor with tenure and then to Professor. He was the holder of the Serena S. Simmons Distinguished Chair in Cancer Immunopharmacology. And he also served as the Howard Hughes Medical Institute (HHMI) Investigator.
He was elected Fellow of the American Association for the Advancement of Science (AAAS) in 2012 and Board Member of Chinese Biological Investigator Society (CBIS) in 2018.
Co-founder and Director
Tingliang Wang, Ph.D. co-founded Westlake Pharmaceuticals in 2020 and serves as its Director.
Dr. Wang is currently the Assistant to the President of Westlake University, a member of the Party Committee of Westlake University, Communist Party of China and the Deputy Director of Westlake Laboratory of Life Sciences and Biomedicine (WLLSB). He also serves as the Chairman of Westlake University Development Limited Co., Ltd. and Westlake University Equity Investment Limited Co., Ltd., as well as a member of the Zhejiang Provincial Government's Bioeconomic Development Expert Advisory Committee.
Dr. Wang received his bachelor's degree in biochemistry from Wuhan University and his Ph.D. in biology from the Hong Kong University of Science and Technology.
He has previously worked as a researcher at the MRIN Nanotechnology Research Institute of Lippo Group and an associate professor at Tsinghua University School of Medicine.
Co-founder and Director
Qi Hu, Ph.D. co-founded Westlake Pharmaceuticals in 2020 and serves as its Director.
Dr. Hu is a principal investigator in the School of Life Sciences at Westlake University and the Deputy Director of the Key Laboratory of Structural Biology of Zhejiang Province.
Dr. Hu received his bachelor’s degree in pharmaceutical sciences and master’s degree in medicinal chemistry from Peking University. He then joined Tsinghua University and received his Ph.D. in biology.
In 2015, he joined Prof. Kevan Shokat’s lab in the University of California, San Francisco for postdoctoral training. Dr. Hu was awarded the prestigious Damon Runyon Postdoctoral Fellowship in 2015.
Co-founder and Director
Jing Huang, Ph.D. co-founded Westlake Pharmaceuticals in 2020 and serves as its Director.
Dr. Huang is a principal investigator in the School of Life Sciences at Westlake University and the Director of AI Therapeutics Lab at Westlake Laboratory of Life Sciences and Biomedicine (WLLSB).
He is a leading figure in both Computer-Aided Drug Design(CADD) and Artificial Intelligence-Driven Drug Design (AIDD) in China, providing scientific consulting services to AI-driven pharmaceutical companies such as XtalPi and DP Technology, as well as top Internet companies such as ByteDance, Baidu (BioMarker Technologies), and Tencent, and conducting related research in collaboration with these companies.
He received his bachelor’s degree and master’s degree in physics at Tsinghua University, and his Ph.D. in chemistry at University of Basel in Switzerland. He did his postdoctoral training from 2012 to 2017 in the Computer-Aided Drug Design Center in University of Maryland School of Pharmacy. In 2015 he was awarded a research contract from National Institute of Health (NIH), and thus held a joint appointment in the Laboratory of Computational Biology at the National Heart, Lung, and Blood Institute, NIH.
